Biota Pharmaceuticals to Host Conference Call to Report Second Quarter Fiscal Year 2016 Financial Results on February 5, 2016...
30 January 2016 - 1:00AM
Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) (the “Company”), a
biopharmaceutical company focused on the discovery and development
of direct-acting antivirals that address infections that have
limited therapeutic options, announced today that management will
host a conference call on Friday, February 5, 2016 at 9:00 a.m. ET
to review the Company’s financial results for the three month
period ended December 31, 2015 and provide an update on recent
corporate developments. The Company will issue a press release
summarizing its financial results the same day, prior to the
conference call.
In order to participate in the conference call, please dial
(877) 312-5422 (domestic) or (253) 237-1122 (international) and
refer to conference ID number 31712361. The live webcast can be
accessed under the Investors section of the Company’s website at
www.biotapharma.com or you may use the link:
http://edge.media-server.com/m/p/pa9bmsp5.
About Biota Pharmaceuticals,
Inc.
Biota Pharmaceuticals is focused on the
discovery and development of direct-acting antivirals to treat
infections that have limited therapeutic options and affect a
significant number of patients globally. The Company has three
product candidates in active clinical development: These include
vapendavir, an oral treatment for human rhinovirus infections in
moderate-to-severe asthmatics currently being evaluated in the
Company’s ongoing Phase 2b SPIRITUS trial; BTA585, an oral fusion
protein inhibitor in Phase 1 development for the treatment and
prevention of respiratory syncytial virus (RSV) infections; and
BTA074, a topical antiviral treatment in Phase 2 development for
condyloma caused by human papillomavirus types 6 & 11. For
additional information about the Company, please visit
www.biotapharma.com.
Contact:
Mark Colonnese
Executive Vice President and Chief Financial Officer
Biota Pharmaceuticals, Inc.
(678) 221-3381
m.colonnese@biotapharma.com
Beth DelGiacco
Stern Investor Relations, Inc.
(212) 362-1200
beth@sternir.com
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Oct 2023 to Oct 2024